@mx_pocketdrama_ca: 14.mp4

Pocket_Drama
Pocket_Drama
Open In TikTok:
Region: CA
Tuesday 18 August 2026 22:00:14 GMT
241868
6393
53
121

Music

Download

Comments

max435874
Boon :
whybchange the bracelet????
2026-08-28 09:10:07
4
bedatismycat
bedatismycat :
Is that you Danny Grover😂😂😂
2026-08-28 01:11:49
5
eranico.0518
EraNionna ❤️‍🔥 :
2026-08-29 00:17:53
0
dam126394
🎭🅰️dam :
up
2026-08-28 20:32:20
0
cherrybethmatugui
cherrybethmatugui :
2026-08-28 12:36:06
0
user4946948087881
Anna :
2026-08-28 05:45:53
0
jenieroseespino
😝J🍀D🍃E🍀🦋🤪✨😘🫰🤞 :
😁
2026-08-27 14:17:50
0
novrianaanna
Novrianna Anna :
haha
2026-08-28 08:01:36
0
badette0816
Badette-08 :
Nice story i love it
2026-08-27 10:36:58
2
queenrizaprajesclemen
mi amor 💕❤️ :
too many ads
2026-08-28 08:58:26
3
estherjoy_o07
estherjoy_o07 :
I dint get the logic of the butler taking the relic for suspicion and then getting happy that Eric about to get laid
2026-08-28 04:59:32
3
attie.manenye
Attie Manenye :
what's with the boob's 😳😳😳
2026-08-28 20:08:19
0
heyruddinbarbarossa
Hairi Mohd :
bapak jarum dia besar
2026-08-27 10:49:05
2
silent.gold49
SILENT GOLD :
which one is take off your pant Abi nah my ear dey hear another thing
2026-08-28 22:11:57
0
noks127
Nokutula Mncwango :
So, he sleeps with his clothes on?
2026-08-29 00:15:38
0
To see more videos from user @mx_pocketdrama_ca, please go to the Tikwm homepage.

Other Videos

Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close.   Note: I have not been compensated in any way for this post/interview.  #Foundayo #newGLP-1 #GLP-1pill #EliLilly
Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close. Note: I have not been compensated in any way for this post/interview. #Foundayo #newGLP-1 #GLP-1pill #EliLilly

About